Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 358

1.

Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.

Findlow H, Sow S, Borrow R, Tapia M, Haidara FC, Akinsola AK, Idoko OT, Diallo F, Adegbola R, Tang Y, Parulekar V, Chadha H, Mabey L, Holme D, Townsend K, Chaumont J, Laforce FM, Kulkarni PS, Marchetti E, Viviani S, Hassan-King M, Preziosi MP.

Clin Vaccine Immunol. 2011 Sep;18(9):1492-6. doi: 10.1128/CVI.05020-11. Epub 2011 Jul 13.

2.

Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.

Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, Tapia M, Akinsola AK, Arduin P, Findlow H, Elie C, Haidara FC, Adegbola RA, Diop D, Parulekar V, Chaumont J, Martellet L, Diallo F, Idoko OT, Tang Y, Plikaytis BD, Kulkarni PS, Marchetti E, LaForce FM, Preziosi MP.

N Engl J Med. 2011 Jun 16;364(24):2293-304. doi: 10.1056/NEJMoa1003812.

3.

A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.

McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C.

Pediatr Infect Dis J. 2012 Jan;31(1):e15-23. doi: 10.1097/INF.0b013e31823e1e34.

PMID:
22094636
4.

Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.

Tejedor JC, Merino JM, Moro M, Navarro ML, Espín J, Omeñaca F, García-Sicilia J, Moreno-Pérez D, Ruiz-Contreras J, Centeno F, Barrio F, Cabanillas L, Muro M, Esporrin C, De Torres MJ, Caubet M, Boutriau D, Miller JM, Mesaros N.

Pediatr Infect Dis J. 2012 Oct;31(10):1074-7.

PMID:
22828645
5.

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.

Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L.

Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S77-88. doi: 10.1097/INF.0b013e318199f609.

PMID:
19325450
6.

Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.

Southern J, Deane S, Ashton L, Borrow R, Goldblatt D, Andrews N, Balmer P, Morris R, Kroll JS, Miller E.

Clin Diagn Lab Immunol. 2004 Nov;11(6):1100-4.

8.

Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.

Holme D, Findlow H, Sow SO, Idoko OT, Preziosi MP, Carlone G, Plikaytis BD, Borrow R.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S563-9. doi: 10.1093/cid/civ505.

9.

Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls.

Borrow R, Southern J, Andrews N, Peake N, Rahim R, Acuna M, Martin S, Miller E, Kaczmarski E.

Vaccine. 2001 Apr 30;19(23-24):3043-50.

PMID:
11311998
10.

The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.

Gatchalian S, Palestroque E, De Vleeschauwer I, Han HH, Poolman J, Schuerman L, Dobbelaere K, Boutriau D.

Int J Infect Dis. 2008 May;12(3):278-88. Epub 2007 Nov 5.

11.

Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.

Hirve S, Bavdekar A, Pandit A, Juvekar S, Patil M, Preziosi MP, Tang Y, Marchetti E, Martellet L, Findlow H, Elie C, Parulekar V, Plikaytis B, Borrow R, Carlone G, Kulkarni PS, Goel A, Suresh K, Beri S, Kapre S, Jadhav S, Preaud JM, Viviani S, LaForce FM.

Vaccine. 2012 Oct 5;30(45):6456-60. doi: 10.1016/j.vaccine.2012.08.004. Epub 2012 Aug 13.

PMID:
22898557
12.

A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana.

Hodgson A, Forgor AA, Chandramohan D, Reed Z, Binka F, Bevilacqua C, Boutriau D, Greenwood B.

PLoS One. 2008 May 14;3(5):e2159. doi: 10.1371/journal.pone.0002159.

13.

Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.

Hu JL, Tao H, Li JX, Dai WM, Song B, Sun JF, Liu P, Tang J, Liu WY, Wang SY, Zhu FC.

Hum Vaccin Immunother. 2015;11(5):1120-8. doi: 10.1080/21645515.2015.1033592.

14.

Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.

Omeñaca F, Arístegui J, Tejedor JC, Moreno-Perez D, Ruiz-Contreras J, Merino JM, Muro Brussi M, Sánchez-Tamayo T, Castro Fernandez J, Cabanillas L, Peddiraju K, Mesaros N, Miller JM.

Pediatr Infect Dis J. 2011 Nov;30(11):e216-24. doi: 10.1097/INF.0b013e3182293a82.

PMID:
21747321
15.

Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).

Østergaard L, Van der Wielen M, Bianco V, Miller JM.

Int J Infect Dis. 2013 Mar;17(3):e173-6. doi: 10.1016/j.ijid.2012.10.001. Epub 2012 Dec 13.

16.

Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age.

Al-Mazrou Y, Khalil M, Borrow R, Balmer P, Bramwell J, Lal G, Andrews N, Al-Jeffri M.

Infect Immun. 2005 May;73(5):2932-9.

17.

The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.

Dbaibo G, Van der Wielen M, Reda M, Medlej F, Tabet C, Boutriau D, Sumbul A, Anis S, Miller JM.

Int J Infect Dis. 2012 Aug;16(8):e608-15. doi: 10.1016/j.ijid.2012.04.006. Epub 2012 Jun 14.

18.

Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine.

El Bashir H, Heath PT, Papa T, Ruggeberg JU, Johnson N, Sinha R, Balfour G, Booy R.

Vaccine. 2006 Mar 24;24(14):2544-9. Epub 2005 Dec 27.

PMID:
16417952
19.

Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine.

Schmitt HJ, Maechler G, Habermehl P, Knuf M, Saenger R, Begg N, Boutriau D.

Clin Vaccine Immunol. 2007 Apr;14(4):426-34. Epub 2007 Feb 7.

20.

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.

Diallo A, Sow SO, Idoko OT, Hirve S, Findlow H, Preziosi MP, Elie C, Kulkarni PS, Parulekar V, Diarra B, Cheick Haidara F, Diallo F, Tapia M, Akinsola AK, Adegbola RA, Bavdekar A, Juvekar S, Chaumont J, Martellet L, Marchetti E, LaForce MF, Plikaytis BD, Enwere GC, Tang Y, Borrow R, Carlone G, Viviani S.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S521-30. doi: 10.1093/cid/civ518.

Supplemental Content

Support Center